For more than five years, the pharmaceutical industry and PBMs have successfully avoided disclosing the true prices of prescription drugs. This lack of transparency persists despite repeated efforts to change it. As a result, pharmaceutical companies are once again eluding demands for public price disclosure. The true prices of medicines remain unknown to the public and patients. This situation hinders better access to information on the cost of treatment. The problem is particularly relevant for prescription medicines in the US.